Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook



 

Four gene mutations lower heart attack risk

23 June 2014

By Dr Charlotte Warren-Gash

Appeared in BioNews 759

Four rare gene mutations may protect against heart attacks by lowering levels of a type of fat called triglycerides, according to research in the New England Journal of Medicine.

Triglyceride levels in the blood were 39 percent lower in carriers of the mutations, which affect the APOC3 gene, than in non-carriers.

Researchers analysed blood from nearly 4,000 participants from the USA's National Heart, Lung and Blood Institute's Exome Sequencing Project. Around one in every 150 people carried an APOC3 mutation and were found to have a 40 percent reduced risk of heart attacks.

'Based on our findings, we predict that lowering triglycerides specifically through inhibition of APOC3 would have a beneficial effect by lowering disease risk', said Professor Alex Reiner, senior co-author of the study from the University of Washington.

Heart problems are known to be linked to levels of a type of cholesterol, low density lipoproteins (LDL). But the role of other blood lipids such as high density lipoproteins (HDL) and triglycerides in heart disease is less clear.

Dr Sekar Kathiresan, director of preventive cardiology at Massachusetts General Hospital, senior author of the study, said: 'HDL and triglycerides are both correlated with heart attack, and have an inverse relationship with one another – the lower the HDL the higher the triglycerides'.

'It has long been presumed that low HDL is the causal factor in heart disease and triglycerides are just along for the ride. But our genetic data indicate that the true causal factor may not be HDL after all, but triglycerides', he added.

Current heart disease prevention therapies such as statins target raised levels of LDL, the so-called 'bad cholesterol'. However some patients go on to have further heart attacks even after being treated with drugs to lower LDL. This study helps to explain the origins of this residual risk.

'Although statins remain a powerful arrow in the quiver, the notion of residual risk of coronary heart disease continues to be a significant clinical problem', commented Dr Kathiresan. 'Our study really reinvigorates the idea of lowering triglycerides and specifically by blocking APOC3 as a viable therapeutic strategy for addressing residual risk'.

SOURCES & REFERENCES
Broad Institute, Massachusetts General Hospital (press release) | 18 June 2014
 
Genetic Engineering and Biotechnology News | 19 June 2014
 
New England Journal of Medicine | 18 June 2014
 
Forbes | 19 June 2014
 
CBS News | 19 June 2014
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

23 May 2016 - by Rachel Reeves 
A rare genetic mutation reduces the risk of having a heart attack by one-third, a study has found...
15 December 2014 - by Dr Molly Godfrey 
Scientists have identified a set of rare gene mutations that may increase the risk of early heart attacks...
18 November 2014 - by Dr Lanay Griessner 
An inactive copy of a gene associated with cholesterol levels can reduce the risk of a heart attack, according to a study...

16 June 2014 - by Dr Kimberley Bryon-Dodd 
Genes linked to cholesterol levels have been successfully edited in mice who received a single injection, thereby reducing their risk of heart disease, according to a study...
02 June 2014 - by Dr Nicoletta Charolidi 
A genetic test that can predict a preventable form of heart disease is being introduced into several NHS hospitals...
12 May 2014 - by Dr Greg Ball 
Two major reviews of clinical trials using stem cells to treat advanced heart disease have found a positive effect of the stem cell treatment, but caution against overstating this effect until more trials are carried out...
06 May 2014 - by Dr Rachael Panizzo 
Heart cells derived from human embryonic stem cells are capable of regenerating damaged heart muscle in primates, a US study has found...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation